Has anyone had their CA 19-9 drop from the thousands to normal levels? What was your starting number and how long...
I can't speak from personal experience, since I'm an educational AI assistant and not a patient. But a drop from 2100 to 680 over 10 weeks is a meaningful change (roughly a 68% reduction), and I can explain how doctors think about CA 19-9 and resectability. Hearing from other patients is valuable, so the Cholangiocarcinoma Foundation and similar communities (listed in the NCCN patient guide's resources section) can connect you with people who have been through this.
1) Has anyone had their CA 19-9 drop from the thousands to normal?
My knowledge base doesn't include individual patient stories or a specific statistic on how often CA 19-9 falls from the thousands to normal, so I can't give you a reliable number. Here is what the guidelines do say:
- According to NCCN Guidelines for Patients: Gallbladder and Bile Duct Cancers (2026), tumor biomarkers like CA 19-9, CEA, and AFP can help with diagnosis, show how well treatment is working, and track cancer growth.
- CA 19-9 behaves differently from person to person. Some people with biliary tract cancers never make much of it, and elevated levels can also come from bile duct blockage or infection (cholangitis), not only from tumor activity. If your bilirubin was elevated at the start, relieving a blockage with a stent or drainage can lower CA 19-9 independent of tumor shrinkage. That is a useful thing to clarify with your team.
Questions to ask your oncologist:
- Was my starting CA 19-9 affected by a bile duct blockage or infection?
- How much of this drop do you think reflects true tumor response?
2) What was your starting number, and how long did it take?
I can't share a personal starting number, but I can say that timelines vary widely, and there is no standard "time to normal" in the sources I have. Your regimen of gemcitabine, cisplatin, and pembrolizumab is one of the options NCCN lists as preferred for unremovable biliary tract cancers (pembrolizumab with gemcitabine and cisplatin is listed alongside durvalumab with gemcitabine and cisplatin).
What matters most is that CA 19-9 is only one piece of the picture. NCCN's surveillance and treatment-monitoring approach pairs CA 19-9 and CEA with multiphasic CT or MRI imaging. Your team will likely weigh your trend (still falling, plateauing, or rising) alongside how the tumor looks on scans.
3) "I've been told I might have a shot at resection, but that number has to come down."
I can't tell you what CA 19-9 level your surgeons need, and I wouldn't want to give you a number that may not apply to you. According to NCCN, the decision about whether a tumor can be removed is made through a multidisciplinary review, meaning surgeons, medical oncologists, radiologists, and others look at your case together. The NCCN patient guide also notes that systemic drug therapy is sometimes given before surgery to reduce the amount of cancer and make the tumor easier to remove.
Doctors generally consider several things together when judging resectability:
- Imaging: Does the tumor involve key blood vessels, spread throughout the liver, or reach distant sites?
- Response to treatment: Is the tumor shrinking or stable on CT or MRI?
- Biomarker trend: Is CA 19-9 moving in the right direction?
- Your overall health and liver function: Can your body safely tolerate surgery?
- Whether staging laparoscopy is needed: This can reveal small spread missed on scans.
Seeking treatment or a second opinion at a high-volume center with hepatobiliary surgery expertise is also recommended by NCCN, since centers that perform many of these surgeries often have better results.
Questions to ask your care team:
- What specific CA 19-9 level or trend are you hoping to see before surgery, and why?
- What do my latest scans show, and how do they factor into resectability?
- How many more cycles are planned before we reassess for surgery?
- Would a second opinion from a high-volume hepatobiliary surgical center be helpful?
- If surgery happens, what treatment would follow? (NCCN lists capecitabine as the preferred after-surgery option for many cases.)
Summary
- Strong guideline coverage: How CA 19-9 is used in monitoring, how resectability decisions are made, and the role of treatment before surgery.
- Limited coverage: Individual patient experiences, the specific CA 19-9 threshold for resection, and how often levels normalize. These are best discussed with your oncologist and surgeon, and peer support communities can offer personal stories.
A falling CA 19-9 alongside a treatment plan that includes surgical evaluation is encouraging context to bring to your next appointment. Your oncologist and surgical team will determine the most appropriate path based on your complete clinical picture.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 20, 2026. Informational only — not a substitute for your oncology team.
Question asked:
Has anyone had their CA 19-9 drop from the thousands to normal levels? What was your starting number and how long did it take? I have been told I might have a shot at resection but that number has to come down. I started at 2100 and now down to 680 after 10 weeks of gemcitabine, cisplatin and pembrolizumab.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for Cholangiocarcinoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Cholangiocarcinoma
- Hello everyone, I would like to ask if anyone here, or anyone you know, has experience using ivermectin and...
- Patients with the KRAS G12A mutation. Does anyone know about this. Pls suggest any target medicine
- Anyone in chicago area and getting treatment by a doctor who specializes in this? My mom was recently diagnosed and...
- Radiation My husband was supposed to start radiation for positive margins in October, he had the CT planning and...
- My mom was diagnosed with stage 3 cholangiocarcinoma in December. She had the Whipple surgery early January. Two...
- Just wondering whether anyone is experience what I'm going through right now. After chemo, surgery, and post-surgery...
- Non operable tumor Hi I’m new to the group and my mom has a bile Duct tumor that it’s not operable (2.7cm) she went...
- I just started Capecitabine last week. No immediate side effects. Then yesterday, my lips started burning and...